secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2023-12-29T23:59:59+00:00
Accession:  0001193125-23-306032
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon enters $75M at-the-market equity offering agreement with Jefferies
--------------------------------------------------------------------------

- Company may sell up to $75M of common stock through Jefferies in at-the-market offerings.
- Jefferies receives 3.0% commission on gross proceeds; company also reimburses legal fees.
- Invus affiliate (largest stockholder) has right to purchase shares to maintain ownership, subject to conditions.
- Proceeds intended to fund commercial launch of INPEFA (sotagliflozin), R&D, and working capital.
- Shares issued under existing shelf registration; prospectus supplement filed Dec 29, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000119312523306032/0001193125-23-306032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000119312523306032/d673597d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-306032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer